Generation Bio Co. (GBIO)
$3.1837
-0.03 (-0.97%)
Rating:
Recommendation:
-
| Symbol | GBIO |
|---|---|
| Price | $3.1837 |
| Beta | 2.223 |
| Volume Avg. | 0.12M |
| Market Cap | 249.375M |
| Shares () | - |
| 52 Week Range | 3.1-7.35 |
| 1y Target Est | - |
| DCF Unlevered | GBIO DCF -> | |
|---|---|---|
| DCF Levered | GBIO LDCF -> | |
| ROE | -42.37% | Strong Sell |
| ROA | -29.42% | Sell |
| Operating Margin | - | |
| Debt / Equity | 31.71% | Neutral |
| P/E | -1.82 | Sell |
| P/B | 0.82 | Buy |
Latest GBIO news
About
Download (Excel)Dr. Cameron Geoffrey McDonough M.D.
Healthcare
Biotechnology
NASDAQ Global Select
Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.